Over at Genetic Future, Daniel MacArthur is wondering what everyone wants to know: why buy Navigenics' Annual Insight service for $500 when you can have 23andMe's full genome scan for $100 cheaper? Navigenics recently announced an alternative to its $2,500 genetic testing service, the Annual Insight service, which costs $499 and analyzes genetic predisposition for ten common health conditions, including breast cancer, prostate cancer, colon cancer, and heart disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.